Galmed Pharmaceuticals Ltd. Stock News

Now could be a great time for investors to consider stacking up on penny stocks. These companies often have significant growth potential.

Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is on the move Thursday after the company priced a public offering of its shares. Galmed Pharmaceuticals intends to offer up 6,578,947 shares of GLMD stoc

Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is gaining on Friday after the company announced an investment agreement with OnKai . That agreement has Galmed Pharmaceuticals making a $1.5 million equit

Galmed Pharmaceuticals (GLMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD ) Q4 2021 Earnings Conference Call May 2, 2022 8:30 AM ET Company Participants Allen Baharaff - President and CEO Yohai Stenzler - Chief Accounting Officer Con

Galmed Pharmaceuticals Ltd (GLMD) shares closed this week 21.3% lower than it did at the end of last week. The stock is currently down 10.4% year-to-date, down 52.3% over the past 12 months, and down 60.7% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Shares traded as high as $2.10 and as low as $1.54 this week.Shares closed 73.1% below its 52-week high and 9.1% above its 52-week low.Trading volume this week was 432.0% higher than the 10-day average and 877.5% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -587.2% The company's stock price performance over the past 12 months lags the peer average by 29.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Galmed Pharmaceuticals Ltd (GLMD) shares closed today 13.5% lower than it did at the end of yesterday. The stock is currently up 3.6% year-to-date, down 44.9% over the past 12 months, and down 53.5% over the past five years. Today, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $2.18 and as low as $1.54 this week.Shares closed 73.9% below its 52-week high and 5.2% below its 52-week low.Trading volume this week was 56.5% lower than the 10-day average and 79.8% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -246.4% The company's stock price performance over the past 12 months lags the peer average by 4.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Galmed Pharmaceuticals Ltd (GLMD) shares closed 5.2% lower than its previous 52 week low, giving the company a market cap of $47M. The stock is currently up 3.6% year-to-date, down 44.9% over the past 12 months, and down 53.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 89.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -246.4% The company's stock price performance over the past 12 months lags the peer average by 4.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

NEW YORK , Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZNGA, RVPH, MOLN, GLMD, and PLTK. Full story available on Benzinga.com

Galmed Pharmaceuticals Ltd (GLMD) shares closed 0.6% lower than its previous 52 week low, giving the company a market cap of $45M. The stock is currently down 41.8% year-to-date, down 44.1% over the past 12 months, and down 50.7% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 244.1% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 12.7% The company's stock price performance over the past 12 months lags the peer average by 24.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Analysts predict that Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) will announce earnings of ($0.32) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Galmed Pharmaceuticals earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.41). Galmed Pharmaceuticals posted earnings per share of ($0.48) in the same quarter last year, []

Brokerages expect Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) to announce earnings per share (EPS) of ($0.32) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Galmed Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.41) and the highest estimate coming in at ($0.23). Galmed Pharmaceuticals reported earnings per share of []

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.87 and traded as low as $2.70. Galmed Pharmaceuticals shares last traded at $2.70, with a volume of 52,631 shares traded. Separately, Zacks Investment Research cut shares of Galmed Pharmaceuticals []

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript